Edition:
United States

Zhejiang Hisun Pharmaceutical Co Ltd (600267.SS)

600267.SS on Shanghai Stock Exchange

13.81CNY
10:29pm EST
Change (% chg)

¥-0.04 (-0.29%)
Prev Close
¥13.85
Open
¥13.90
Day's High
¥13.95
Day's Low
¥13.75
Volume
3,621,727
Avg. Vol
6,954,400
52-wk High
¥15.08
52-wk Low
¥9.92

600267.SS

Chart for 600267.SS

About

Zhejiang Hisun Pharmaceutical Co.,Ltd. is principally engaged in the manufacture and distribution of pharmaceuticals. The Company's products include antineoplastic drugs, cardiovascular drugs, anti-infection drugs, endocrine control drugs, anthelmintic, as well as animal remedies, among others. The Company also involves in the... (more)

Overall

Beta: 1.10
Market Cap(Mil.): ¥13,391.93
Shares Outstanding(Mil.): 965.53
Dividend: 0.07
Yield (%): 0.50

Financials

  600267.SS Industry Sector
P/E (TTM): 333.65 28.84 29.63
EPS (TTM): 0.04 -- --
ROI: 1.66 13.44 12.96
ROE: 0.58 14.34 14.11

BRIEF-Zhejiang Hisun Pharmaceutical sees FY 2016 net profit up 260 pct to 300 pct

* Sees net profit for FY 2016 to increase by 260 percent to 300 percent

Jan 25 2017

BRIEF-Zhejiang Hisun Pharmaceutical appoints Guan Xuhua as CFO

Dec 17 Zhejiang Hisun Pharmaceutical Co Ltd : * Says it appoints Guan Xuhua as CFO to replace Hu Liangbin Source text in Chinese: https://goo.gl/aWixl4 Further company Coverage: (Beijing Headline News)

Dec 17 2016

BRIEF-Zhejiang Hisun Pharmaceutical's share trade to resume on Nov 21

Further company coverage: (Reporting by Hong Kong newsroom)

Nov 18 2016

BRIEF-Zhejiang Hisun Pharmaceutical gets nod for clinic trial

* Says it gets China Food and Drug Administration's approval for three original chemical drugs' clinic trial

Nov 07 2016

BRIEF-Zhejiang Hisun Pharmaceutical to apply for comprehensive credit line of 300 mln yuan

* Says it will apply for a comprehensive credit line of up to 300 million yuan from China Merchants Bank with a term of two years

Oct 31 2016

BRIEF-Zhejiang Hisun Pharmaceutical unit gets FDA approval

* Says its unit receives ANDA approval for its irbesartan and hydrochlorothiazide tablets from U.S Food and Drug Administration

Oct 20 2016

BRIEF-Zhejiang Hisun Pharma plans share issue to fund project, repay loans

* Says it aims to raise up to 1.2 billion yuan ($179.95 million)in private placement of shares to fund project, repay bank loans

Oct 17 2016

BRIEF-Zhejiang Hisun Pharmaceutical's shares to halt trade pending private placement plan

* Says its shares to halt trading from Sept 9 pending private placement plan

Sep 08 2016

More From Around the Web

Earnings vs. Estimates